Phosphatidylcholine is a key component of the mucosal barrier. Treatment with modifi ed release phosphatidylcholine aims to improve the impaired barrier function. The primary objective is to evaluate the effi cacy of LT-02, a newly designed modifi ed release phosphatidylcholine formula, in a multicenter setting.
INTRODUCTION
Ulcerative colitis (UC) is an infl ammatory bowel disease that aff ects the distal colon, potentially spreading over the entire colon. Th e incidence is 5 -20 / 100,000 in western countries, with a prevalence of 0.02 -0.23 % ( 1 ). First-line pharmacotherapy consists of 5-aminosalicylic acids and / or steroids for acute episodes. Aminosalicylates and thiopurines, but not steroids, should be used for maintenance therapy. Calcineurin and tumor necrosis factor-α antagonists may work in refractory cases, but the eff ects wear off over time and adverse events can be limiting (( 2 -5 ); see also FDA block warning on tumor necrosis factor blockers). Moreover, tumor necrosis factor antibodies are highly cost intensive. Current therapeutic regimens therefore are not always successful. Th e 10-year cumulative risk of colectomy is ~ 9 % ( 6 ). An unmet medical need for a safe and eff ective therapy remains.
Phosphatidylcholine (PC) was found to be an essential protective component of colonic mucus ( 7 -9 ) . Th e novel treatment of modifi ed release PC was based on the observation that specifi cally patients with UC had a low intrinsic mucus PC content that reduces the hydrophobic barrier function of the intestinal mucus ( 10, 11 ) . Colonic bacteria may then permeate the intestinal mucus barrier, and the consecutive unspecifi c but aggressive immune responses lead to infl ammation and ulceration ( 12 ) . Moreover, the intrinsic anti-infl ammatory property of PC is lacking which, in turn, perpetuates the mucosal damage ( 13, 14 ) . Th e purpose of modifi ed release PC is to reconstitute the low mucus PC reservoir and to re-establish the mucosal barrier ( 9,15 -17 ) . Th ree previous studies have shown effi cacy using a modifi ed release preparation of soy lecithin containing 30 % PC ( 18 -20 ) . Th e altered bioavailability of modifi ed release PC aims to release PC in the distal ileum, thereby avoiding early intestinal absorption. Th e formula was optimized to LT-02, which contains > 94 % PC concentrated soy lecithin, to allow for regulatory approval.
Th e goal of the present trial was to evaluate the clinical effi cacy, optimal dose, and safety of LT-02.
METHODS
We calculated 160 patients with mesalazine-refractory UC for the screening phase in order to randomize 144 patients. A planned interim analysis included the possibility of increasing the sample size if necessary. Th e main inclusion criteria were as follows: an active disease with the Simple Clinical Colitis Activity Index (SCCAI) of ≥ 5 and a subscore for " blood in stool " of ≥ 2 at baseline; a history of bloody diarrhea for at least 6 weeks before inclusion despite mesalazine treatment at a dose of ≥ 3 g / day; or a documented intolerance to mesalazine (for details of criteria, see legend of Figure 1 ). Patients were required to maintain a stable comedication throughout the study; steroid tapering was not allowed. UC was defi ned in accordance with the European consensus conference ( 21 ) . Recruitment took place in 24 referral centers in Germany, Lithuania, and Romania. Th e Contract Research Organization (CRO) produced computer-generated randomization lists for every study center with the allocation of 1:1:1:1 in blocks of 4. Th e study interventions consisting of three diff erent doses of LT-02 (0.8, 1.6, and 3.2 g) were tested against placebo and were provided in sequentially numbered containers. Doses were selected based on the results of the previous studies ( 18 -20 ) . Th e study medication was provided in sachets with pellets taken orally four times daily. Th e study medication was produced, packed, and labeled according to Good Manufacturing Practice and stored at 2 -8 ° C.
Patients were interviewed, examined, and screened for eligibility at the screening visit (V1, for inclusion and exclusion criteria see legend of Figure 1 ). Patients to be included received detailed study information, gave written informed consent, and were instructed in completing the study diary (comprising SCCAI and other interview parameters). Stool samples were taken to exclude for infectious enterocolitis (including Clostridium diffi cile and Escherichia coli 0157:H7). If the patient was still eligible aft er 1 week of screening (V2 = baseline), a safety lab was taken and a sigmoidoscopy / colonoscopy was performed. At the interim visits 2 and 6 weeks aft er baseline (V3 and V4), possible disease exacerbation and changes in medication or adverse events (AEs) were assessed. Th e treatment period ended 12 weeks aft er baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment. Th e maximal duration of the study was 21 weeks per patient: a 1-week screening period plus 12 weeks of treatment period; patients reaching partial or complete remission (SCCAI < 5 at end of treatment) underwent an additional 8-week follow-up without study medication (see Appendix Figure A1 ).
Patients could discontinue the study at any time without reason. Th e investigator could withdraw a patient in case of AEs or disease exacerbation or if therapeutic intervention was required. Discontinuation criteria were the development of complications such as pseudomembranous colitis, an SCCAI increase of ≥ 7 over baseline, or fever > 39 ° C. Discontinuation because of disease exacerbation was defi ned as an AE. Patients who discontinued the study early qualifi ed as " premature discontinuation " which resulted in a fi nal study visit. Dropouts were not replaced.
Patients ' compliance was monitored by returned sachets, diary entries, and interviews. Th e central ethics committees approved the study protocol in all participating countries. No changes to the study methods were made aft er study initiation.
Precautions against bias
To avoid selection bias, all patients who fulfi lled all criteria were included into the study in the predefi ned, randomized order. Pellets, sachets, and containers were completely indistinguishable between treatment arms. Both patients and study personnel remained blinded and unaware of the allocation method throughout the study until database closure. It was not possible for patients or investigators to guess the next allocated medication in order to avoid selection or allocation biases. To avoid attrition bias, we handled incomplete data in a conservative manner: all patients with premature treatment termination were included in all fi nal analyses with their last available data (last observation
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Study of Modified Releas e PC " LT-02 " in UC carried forward (LOCF)), so that a possible LT-02 treatment eff ect was rather reduced than increased. More placebo patients may have stopped treatment owing to a lack of effi cacy or for other reasons; it is unlikely that the results would have improved if treatment had been continued, and carrying forward the last value appeared to be conservative. All dropouts and losses to follow-up are described in Figure 1 . Individuals with possible confl ict of interest were neither allowed to recruit patients nor were they involved in the conduct or analyses of the study. Th ere were no changes in the study methods or outcome parameters aft er study initiation. All authors had access to the study data and have reviewed and approved this manuscript.
Outcomes
Th e disease activity was assessed using the SCCAI ( 22 ) that is validated and has been proven to correlate well with other indices comprising invasive methods ( 23 -26 ) . Th e primary end point was changes in SCCAI from baseline (V2) to V5. Th e SCCAI assesses stool frequency during the day and at night, defecation urgency, blood in stool, general well-being, abdominal pain, and extraintestinal manifestations. Th e score ranges from 0 to 19 points -the lower the score, the lower the disease activity.
We assessed the following secondary and a priori defi ned end points in an exploratory sense: complete remission ( < 3 mean SCCAI ( 26 ) and " blood in stool " subscore of 0 (see European Crohn ' s and Colitis Organization (ECCO) defi nition of remission ( 21 ), LOCF); partial remission (SCCAI < 5, LOCF); clinical response (SCCAI decrease ≥ 2 ( 26 )); mucosal healing (endoscopic Mayo Score (EMS) ≤ 1); achievement of mucosal healing (EMS ≤ 1 at V5 and improvement of EMS ≥ 1 from V2 to V5); patients with complete remission; and a " bowel frequency " subscore of 0. All SCCAI-based end points refer to the patient ' s mean values of ( 16 )) with an inadequate response to mesalazine for 6 weeks at a dose of ≥ 3 g / day for over 4 weeks or documented intolerance to mesalazine (a documented intolerance required previous doctors ' letters or medical notes that stated that an adverse event possibly related to mesalazine led to a discontinuation of its therapy); active disease with blood in stool for at least 6 weeks; SCCAI ≥ 5 and SCCAI subscore for " blood in stool " ≥ 2 at baseline visit (V2); comedication was allowed if on a stable dose for 4 weeks (e.g., 5-ASA, systemic acting steroids (if taken for ≥ 8 weeks before the start of the study), azathioprine (2 -2.5 mg / kg), 6-mercaptopurine (1 -1.5 mg / kg), both if taken for ≥ 3 months); and a negative pregnancy test at V1 and V2 plus the use of adequate contraception, if applicable. Exclusion criteria were as follows: toxic megacolon or fulminant courses; therapy with cyclosporine, tacrolimus, methotrexate, or TNF-α -antagonists within 3 months before study entry; current treatment with opiates or loperamide; current antibiotic treatment; rectal applications of aminosalicylates, steroids, or budesonide; oral application of topically acting steroids; ulcerative proctitis with a disease extent < 10 cm; infl ammatory or bleeding disorders of the gastrointestinal tract other than UC, or diseases that may cause diarrhea or gastrointestinal bleeding; condition after surgery of the colon; any other uncontrolled systemic diseases (e.g., cardiac, renal, pulmonary, hepatic) or severe chronic diseases (e.g., malignancies, HIV infection); and pregnant or nursing women. 5-ASA, 5-aminosalicylic acid; AE, adverse event; Discont. Intervent., discontinued intervention; INR, international normalized ratio; SCCAI, Simple Clinical Colitis Activity Index; TNF-α , tumor necrosis factor-α ; UC, ulcerative colitis.
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1 week rounded to integer numbers. Time to symptom resolution was defi ned as the fi rst 3 days with ≤ 3 stools per day without visible blood ( 21 ) . Th e EMS is categorized as follows: 0, inactive; 1, mild disease (erythema, decreased vascular pattern, minimal granularity); 2, moderate disease (marked erythema, friability, granularity, absent vascular pattern, bleeding on minimal trauma, no ulcerations); and 3, severe disease (ulceration, spontaneous bleeding). Th e histologic index (by Riley) ranges from 1 representing remission to 4 representing severe colitis; a central pathologist, who was blinded to the groups, assessed the score.
Statistics
Data from a dose-fi nding study ( 19 ) showed that a relative eff ect size for the SCCAI of ~ 0.8 could be expected from the 3.2 g dose group compared with placebo. Under the parametric assumptions of the t -test, 30 patients per group were needed to detect a diff erence of a relative eff ect size of 0.8 between placebo and an active group with a power of 85 % ( α = 0.025, one sided). Th e sample size was increased from 30 to 36 patients per group to accommodate for nonresponse, loss to follow-up, and other deviations from planned study conditions. We also included dose groups of 0.8 and 1.6 g LT-02 to allow for dose-fi nding and dose-response analyses, as the drug LT-02 was new and had not been tested in studies.
Primary analysis was based on the full analysis set (intention to treat) that included all randomized patients. If a patient had a missing value at the fi nal visit (V5), the latest available value was carried forward. Analysis of covariance was used to model the primary end point, including the following baseline covariates: (i) mean SCCAI in the past 7 days of the screening period; and (ii) disease extent. Th e model including these two covariates and the treatment group eff ect was considered to be the core model. It was used to compare the eff ects of placebo and the individual dose groups in fi xed sequence, starting with the highest dose group of 3.2 g LT-02 daily, followed by the lower dose groups in descending order. Th e confi rmatory testing procedure stopped at the fi rst nonsignifi cant result; superiority was given if the one-sided P value was < 0.025, equivalent to a two-sided α level of 0.05.
Survival methods were used to analyze time-to-event variables; the log-rank test compared time with event curves between treatment groups. likelihood ratio χ 2 tests based on nominal logistic regression were planned to compare the results of qualitative variables between treatment groups. Th e analysis plan did not specify how the groups should be compared: in order to increase the statistical power, we focused on the comparisons between placebo and the three active groups pooled.
Th e statistical power to detect treatment eff ects in categorical parameters in this small sample size is far below the usual 80 -90 % . Th is is why we defi ned categorical variables such as rate of remission or mucosal healing a priori as secondary and exploratory, in order to discover trends in treatment eff ects to gather information for the sample-size calculation for future phase III studies.
Linearity was checked for important continuous variables compared with log transformation. Normality for continuous parameters was assumed if the absolute value of skewness was < 1. In addition, the Shapiro -Wilk goodness-of-fi t tests were applied.
A planned interim analysis was conducted by an independent data monitoring committee aft er half of the patients had terminated the treatment period to adjust the sample size or to stop the trial for futility, if indicated.
Soft ware for sample-size estimation included nQuery Advisor V5.0 (Statistical Solutions Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden). Statistical analyses were performed using SAS JMP V9 and SAS JMP V8 and higher (JMP, SAS Institute Inc., Cary, NC) .
RESULTS
Th e study was conducted between November 2009 and December 2010. A total of 175 patients were screened, of which 156 UC patients (119 in Germany, 22 in Lithuania, and 15 in Romania) were randomized and treated (see Figure 1 ). When we received the recommendation of the independent data monitoring committee to continue the study as planned, we had already randomized 12 patients more than the planned 144 patients; the independent data monitoring committee then recommended including these additional patients in the analyses.
In total, 14, 12, 6, and 7 patients of the placebo, 0.8, 1.6, and 3.2 g LT-02 groups, respectively, terminated the study prematurely aft er randomization, most frequently at their own request owing to the lack of effi cacy or AEs. In addition, 18 patients did not return all empty sachets of study medication and were therefore classifi ed as noncompliant (7 placebo, 6 0.8 g LT-02, 2 1.6 g LT-02, and 3 3.2 g LT-02 patients). One placebo patient suff ered a serious adverse event (SAE; atrial fi brillation) and was unblinded prematurely; one patient in the 3.2 g LT-02 group was accidentally unblinded by a peripheral study nurse, but remained single-blinded.
Overall, disease-specifi c baseline characteristics indicated no major diff erences across the four patient groups ( Table 1 ) . Th ere were no relevant country eff ects in the interaction analyses. Concomitant medication was comparable across all study groups, but azathioprine intake was higher in the 0.8 g LT-02 group. Th e mean SCCAI varied from 8.5 to 9.0, which represents a moderately active UC population. Th ere were no colectomies reported during the study or during follow-up.
Effi cacy results
We found a higher absolute SCCAI reduction in all LT-02 groups compared with placebo. In the primary analysis, the disease activity score (SCCAI) in the highest dose group (3.2 g LT-02) dropped from 8.5 to 4.1 (51.7 % ) compared with 9.0 to 6.0 (33.3 % ) in the placebo group (two-sided P value = 0.030, see Figure 2 ; the corresponding one-sided P value is P = 0.015 which met the goal of the study.)
Th e secondary analyses found a remission rate of 31.4 % (11 / 35) in the highest LT-02 dose group compared with 15 % (6 / 40) under placebo ( P = 0.09; two-sided likelihood ratio χ 2 test; Appendix Figure A2 ). Th e response rates increased from 24 / 40 (60 % ) under placebo to 29 / 35 (83 % ) in the highest LT-02 dose group ( P = 0.030;
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two-sided likelihood ratio χ 2 test; Table 2 ). Th e number needed to treat for LT-02 in mesalazine-refractory UC was 6.1 to reach complete remission and 4.3 to reach clinical response. Th e rate for achievement of mucosal healing was 32.5 % in the placebo group compared with 47.4 % in the pooled LT-02 groups ( P = 0.098, Table 2 ); the rate for histologic healing (histologic index = 1) was 20.0 % in the placebo compared with 35.3 % in the LT-02 groups ( P = 0.016). Th e time to fi rst symptom resolution was 33 days in the median among LT-02 responders. Symptom resolution occurred ~ 2 weeks earlier and was almost twice as oft en under LT-02 treatment than under placebo treatment ( P = 0.02; Figure 3 ).
Safety results
Safety evaluations of lab results, vital signs, and physical examinations did not show any treatment-related changes between the study groups. Th e frequency of possibly drug-related AEs was low in all four study arms. Mainly mild or moderate treatment-related AEs occurred. Th ere were 17 treatment-emergent AEs (48.6 % ) in the highest dose group (0 SAEs) compared with 22 (55 % ) in the placebo group (4 SAEs). Th ere were no relevant or signifi cant differences of adverse drug reactions between the treatment groups (see Table 3 ; Appendix Table A2 ). In all, 12 patients experienced The longer duration of disease in the placebo group was not signifi cant ( P > 0.4, Dunnett test, Wilcoxon test). In addition, there was no statistically signifi cant effect on SCCAI ( P =0.22) and no effect modifi cation in the sense of an interaction with treatment ( P =0.29). The comparison between placebo and the highest dose group revealed an estimate of − 1.56 and a two-sided P value of 0.03 with a 95 % confi dence interval of − 2.96 to − 0.16. SCCAI, Simple Clinical Colitis Activity Index.
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Karner et al. 17 SAEs; these consisted of 5, 2, and 1 patient in the 0.8, 1.6, and 3.2 g LT-02 treatment groups, respectively, and 4 patients in the placebo group. Only one SAE, atrial fi brillation, was assessed as being possibly related to study treatment; it occurred in the placebo group.
Follow-up
Responders of all study arms entered an 8-week follow-up period without study medication. Patients in the LT-02 group were able to avoid relapses over a longer period and in a higher percentage of patients ( P = 0.02, log-rank test; Appendix Figure A3 ). Figure 3 . Time to fi rst symptom resolution: all active LT-02 groups pooled vs. placebo. LT-02 patients reached the end point of fi rst symptom resolution more than 2 weeks earlier than placebo ( P = 0.02, preplanned, two-sided log-rank test). In total, almost twice as many LT-02 patients reached complete symptom resolution compared with placebo.
DISCUSSION
Th e aim of the current trial was to evaluate the effi cacy, safety, and optimal dose of a newly designed, modifi ed release formulation of highly purifi ed PC (LT-02). Th is drug is a fi rst-in-class therapy for UC and the fi rst treatment with a mucoprotective substance to reach study phase II or phase III.
Th e primary analysis revealed a statistically signifi cant treatment eff ect for LT-02 in mesalazine-refractory UC: whereas the two lower doses of LT-02 showed improvement that was statistically not signifi cant, the highest LT-02 dose group (3.2 g) showed a signifi cantly higher drop of the index compared with placebo ( P = 0.030, two sided). Mixed modeling was performed as sensitivity analyses for the SCCAI primary model to confi rm the primary analysis: all data of visits under treatment were used as the dependent variable (without applying LOCF), with repeated measures on the same patient taken into account with three diff erent versions of simple covariance structures of residuals. Fixed eff ects included into the mixed model were the same as in the primary model, namely dose group, SCCAI at baseline, and extent of disease. Th e resulting two-sided P values for the primary comparison of 3.2 g LT-02 vs. placebo were between 0.008 and 0.036 depending on the type of the covariance structure used. Th ese analyses confi rmed the statistical signifi cance of the originally planned primary analysis.
SCCAI subcategory analyses revealed that " Extraintestinal Manifestations " showed no signifi cant diff erences between LT-02 and placebo, and this is not surprising for a topical and not systemic agent . " Bowel Movements at Night " indicated a statistical trend with a two-sided P value of 0.127, whereas " Stool Urgency " resulted in a P value of 0.006. (Both categories represent major patient complaints: nightly defecation is highly disruptive and aff ects patients ' recreation; stool urgency requires immediate access to bathrooms, which may result in pain and
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Limitations
Th e primary end point " changes of disease activity index " instead of remission rates is unusual for a larger study. Th e clinical eff ect and the practical impact of treatment may be overestimated with the use of numerical changes, but they detect clinical eff ects in smaller study populations. Information is lost by qualitative variables such as remission rates. Th is is why quantitative target variables are important in dose-fi nding studies, as they have a higher sensitivity concerning dose-response eff ects of a new drug such as LT-02.
On the basis of this primary, quantitative end point, we had planned to include 36 evaluable patients per group. Remission end points require much higher sample sizes of ~ 200 patients per group (equals N = 800 for this study), and these are targeted for pivotal studies. Th e small sample size of the current trial resulted in a reduced statistical power for secondary end points, making statistical signifi cance unlikely. With our small sample size, success rate estimates of qualitative variables have a high variability; statistically signifi cant results or strict dose-response patterns cannot be expected for qualitative parameters such as remission or mucosal healing.
Most pivotal studies in UC use the Mayo score instead of the SCCAI. Th e European Medicines Agency, EMA, however, states that it does not favor any score, but recommends the use of indices using signs and symptoms rather than endoscopy, as this correlates well with the former but varies strongly between observers ( www. tga.gov.au/pdf/euguide/ewp1846306en.pdf ). Th e SCCAI is the most comprehensive clinical score; it requires no diagnostic humiliating stool incontinence.) " Bowel Frequency, " " General Wellbeing, " and " Blood In Stool " show borderline signifi cant P values that are not much higher compared with those of the total SCCAI.
In the main secondary outcome analyses, we found that the clinical and histologic remission rates doubled between placebo and the highest LT-02 dose groups. Approximately 50 % more LT-02 than placebo patients achieved mucosal healing ( P < 0.1, Table 2 ). As the applied LOCF analyses bear the risk of underestimating treatment eff ects ( 27 ), we conducted a sensitivity analysis upon request of reviewers with dropouts treated as failures: the eff ects that we observed magnifi ed and indicated statistical significance ( Table 2 ) . Th e preplanned analyses of clinical response and time to fi rst symptom resolution also revealed statistically significant results ( Figure 3 ). Follow-up analyses revealed that placebo patients relapsed earlier and more frequently than LT-02 patients ( P = 0.02; Appendix Figure A3 ). Th is underlines the LT-02 effi cacy as the placebo eff ect in the placebo group became more apparent. Th e treatment eff ect of LT-02 seems to last longer than the period of actual drug intake. We believe that an interruption of the vicious cycle of barrier defect and mucosal damage might be responsible for this eff ect.
Th e treatment eff ects in mesalazine-refractory UC were good (number needed to treat was 6.1 for complete remission and 4.3 for clinical response), and the safety profi le was excellent: AEs occurred equally among placebo and LT-02 groups and no LT-02-related SAE occurred. There was no evidence for any treatment-related difference of adverse events (AEs). As may be expected from the patient population and the disease under treatment in this study, gastrointestinal AEs as well as infections were the most frequent AEs. Neither these nor other AEs showed any treatment-related differences.
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interventions and allows for continuous evaluation throughout the study. Unlike the Mayo or CAI scores, it allows for time-toevent (remission / response) analyses (see Figure 3 , Appendix Table A1 and Appendix Figure A3 ) that are essential for a new drug with an unknown time to treatment response. Th e SCCAI is a relatively new, but well-established, score that has been used frequently in clinical studies recently. Cutoff points for remission ( < 2.5), relapse ( > 4.5), and response (index drop > 1.5) have been validated ( 24 -26 ) . As the SCCAI only allows for natural numbers, our end points of remission < 3, partial remission ≤ 5, and response (SCCAI drop ≥ 2) are equivalent to these cutoff s.
Of the 24 study centers, 9 had < 4 patients and an additional 7 centers had < 8 patients, and this explains a certain deviation from a better balance between study arms ( N varies between 35 and 41). Th is, however, is not an issue because statistical tests are fi tted more to simple randomization than to restricted randomization.
Th e randomization ratio was 1:1:1:1 with blocks of four per center. Th is could mean a potential limited bias in case of the premature unblinding of a patient, as the investigators might draw conclusions concerning the treatment of the remaining patients at their centers. In an isolated occurrence, a patient was accidentally unblinded by a study nurse. As the investigators were completely uninformed regarding the above-described packaging strategy, it is highly unlikely that this could infl uence the study outcome. A randomization ratio with blocks of eight would have been preferable, but it was fi nancially not feasible.
Some authors expect a two-sided P value for the primary analysis. A one-sided P value, however, is oft en used in regulatory superiority studies with a stricter signifi cance level of P = 0.025 that equals a two-sided P value of 0.05. Inferiority to placebo was not assumed, as previous studies had shown superiority. All presented P values are two sided; only the P value for the primary analysis is presented as both one and two sided to facilitate the comparison with the stricter limit of 0.025.
Fecal calprotectin is an essential marker in UC at present. During the planning phase of the study, however, it was not established and was included into the running study. As the study progressed so fast, the resulting data are too little to be analyzed.
Conclusion
Th ere is a pressing need for treatment alternatives in refractory UC. Th e goal of the study with the a priori defi ned primary end point of changes in disease activity was reached: the disease activity score dropped signifi cantly under 3.2 g LT-02 compared with placebo. Moreover, the drug was found to be very safe. Although the improvement of the disease activity in the lower doses (0.8 and 1.6 g LT-02) was not statistically signifi cant compared with placebo, the highest dose was eff ective and is intended for the planned pivotal studies.
Th e treatment eff ects of modifi ed release PC appear to correlate with the shift of paradigm from immunological disorder to mucosal barrier dysfunction that has taken place in our understanding of infl ammatory bowel disease in recent years. Our fi ndings could possibly further the treatment and understanding of ulcerative colitis. Table A1 . Remission rates over time Placebo ( n =40) 0.8 g LT-02 ( n =40) 1.6 g LT-02 ( n =41) 3.2 g LT-02 ( n =3 5 )
APPENDIX
V3
Complete remission n ( % ) 3 / 38 (7.9 % ) 3 / 38 (7. fulfi lled the study criteria at baseline (V2, 1 week after V1), they were then randomized into the study and received their fi rst study medication at the study center after baseline investigations (interview, physical examination, sigmoidoscopy / colonoscopy, lab tests). At the interim visits 2 and 6 weeks after baseline (V3 and V4w), the Simple Clinical Colitis Activity Index (SCCAI), possible disease exacerbations, changes in medication, and adverse events (AEs) were assessed. The treatment period ended 12 weeks after baseline at V5 that involved the fi nal study assessment (interview, physical examination, lab test, sigmoidoscopy). Responders of all study arms entered a 8-week follow-up period without study medication; those patients were asked to continue their comedication as taken before, unless they relapsed. When adding a normal stool frequency to this defi nition, the remission rate then increased by factor 2.3, from 12.5 % in the placebo group to 28.6 % in the highest LT-02 dose group ( P = 0.105). The blue columns show the rates for partial remission defi ned by an SCCAI < 5. A total of 69 patients who had a time to clinical relapse or information on censoring related to clinical relapse were included in the analysis. Patients treated with LT-02 relapsed later and less frequently than placebo patients (preplanned, two-sided log-rank test, P = 0.016).
